Table 1: Baseline characteristics of included patients.

Patients ()

Male gender40 (34)
Age, years55 [48–62]
BMI, kg/m226 [24–30]
ALT, U/L57 [38–110]
AST, U/L49 [34–81]
Alkaline phosphatases, U/L76 [62–99]
GGT, U/L67 [37–129]
Platelets, ×109/L212 [174–260]
Noninvasive methods
Transient elastography, kPa8.3 [6.4–13.6]
,  kPa65 (56)
,  kPa30 (26)
APRI0.68 [0.43–1.37]
, 27 (23)
, 18 (15)
ELF9.39 [8.70–10.49]
, 59 (50)
, 36 (31)
Liver biopsy
Specimen length, mm20 [10–30]
Portal tracts, 10 [8–12]
Fibrosis, METAVIR
63 (54)
35 (30)
11 (9)
8 (7)

Data expressed as median [interquartile range] or absolute (%). ALT, alanine transaminase; APRI, aspartate-to-platelet-ratio-index; AST, aspartate transaminase; BMI, body mass index; ELF, enhanced liver fibrosis; GGT, gamma-glutamyltransferase; TE, transient elastography. Castéra et al. [19], Wai et al. [20], and Fernandes et al. [21] cut-offs were used for fibrosis staging based on transient elastography, APRI, and ELF, respectively.